Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II

Diabetes treatment cost represents an ever-growing problem. The adoption of new drugs in therapy, although they can guarantee an improvement in patient’s quality of life, can meet obstacles when it involves an increase in costs. We decided to compare the costs and benefits of the new saxagliptin and...

Full description

Bibliographic Details
Main Authors: Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
Format: Article
Language:English
Published: SAGE Publishing 2020-06-01
Series:Health Services Insights
Online Access:https://doi.org/10.1177/1178632920929982

Similar Items

Similar Items